Biliary stricture is a common cause of morbidity after liver transplantation (LT). This study aimed to determine the risk factors for post-transplant biliary anastomotic strictures (BAS), focusing on perioperative platelet counts. We enrolled 771 consecutive recipients who underwent ABOidentical/compatible deceased donor LT with duct-to-duct biliary reconstruction from January 2000 to June 2012. BAS was identified in 142 cases. The median time for stricture development was 176 days. Preoperative and postoperative platelet counts within 5 days after LT were significantly lower in patients with BAS than those without BAS. Using cutoff values acquired by the receiver operating characteristic curve analysis, persistent postoperative thrombocytopenia was defined as platelet counts <41 9 1000/ll and <53 9 1000/ll on postoperative day (POD) 3 and POD 5, respectively. Multivariate analysis indicated persistent postoperative thrombocytopenia (OR = 2.38) was the only independent risk factor for BAS. No significant associations were observed in terms of donor and surgical factors. Multivariate analysis demonstrated estimated blood loss (OR = 1.01, per 100 ml) was an independent contributing factor for persistent postoperative thrombocytopenia. We demonstrated low platelet count was associated with progression of post-transplant BAS. Minimizing intraoperative blood loss potentially contributes to maintain posttransplant platelet count, which may reduce incidence of BAS.
Introduction
Biliary strictures are one of the most common causes of morbidity after liver transplantation (LT) [1] . Despite progress in surgical technique and preservation methods, biliary strictures remain the most common complication after deceased donor LT, with an incidence of 5-15% [1, 2] . Biliary strictures are classified as biliary anastomotic stricture (BAS) or non-BAS. BAS is an isolated stricture at the biliary anastomosis, commonly observed 5-8 months after transplant [3] . Potential causes of BAS include suboptimal surgical technique, suture material, anastomotic tension, and infections, leading to fibrotic scarring of the anastomosis [1] [2] [3] .
Thrombocytopenia is a frequent complication after LT [4] . Common etiologies include sequestration in the liver graft, immunologic reaction, increased consumption, decreased production, and medication side effects [4] [5] [6] . Although severe thrombocytopenia has been reported to increase mortality in several studies [4, 7, 8] , pathophysiology remains unclear. In recent years, platelets have garnered attention for promoting liver regeneration and attenuating liver fibrosis [9] [10] [11] . A prospective clinical trial demonstrated that platelet transfusion in patients with liver cirrhosis attenuated liver fibrosis [11] . In this retrospective clinical study, we investigated the risk factors for progression of posttransplant BAS, focusing on peritransplant platelet counts.
Materials and methods

Study population
Between January 2000 and June 2012, 1044 patients underwent ABO-identical/compatible orthotopic LT from deceased donors at Henry Ford Hospital (Detroit, MI, USA). Patient records were identified by an administrative database. Twenty-eight patients were excluded for incomplete records. Another 204 patients with biliary reconstruction by hepaticojejunostomy were excluded due to the difference in the approach for BAS diagnosis. Forty-one patients with deceased donor LT from donation after cardiac death (DCD) donors were not enrolled because of the well-accepted increased risk of biliary stricture in DCD grafts [12] . Thus, a final population of 771 recipients of brain death donor LT with duct-to-duct biliary reconstruction was enrolled. All data for the current study were collected in accordance with the Henry Ford Hospital Internal Review Board.
Operative procedures
Organ procurement was performed by aortic perfusion, using a standardized technique with the exception of the preservation solution. We used University of Wisconsin solution until 2003 and then switched to histidine-tryptophan-ketoglutarate (HTK) solution thereafter. All patients underwent transplantation according to common implantation techniques. Biliary reconstruction was performed with careful dissection of the hilum to preserve adequate blood supply to the bile duct. After hepatic arterial anastomosis, a biliary reconstruction was performed. The duct-to-duct anastomosis was performed using 6-0 polydioxanone. Hepatic arterial (HA) flow was measured by a flowmeter, Optima Flow-QC Meters â (Transonic Systems Inc, Ithaca, NY, USA). HA flow/graft weight ratio was calculated by HA flow (ml/min)/graft weight (g).
Platelet counts
Peritransplant platelet counts were recorded daily from admission until discharge and followed up at the outpatient clinic. We classified patients as having either a low or high platelet count on each postoperative day (POD), using the cutoff value calculated by the receiver operating characteristic (ROC) curve analysis and the Youden Index. Persistent postoperative thrombocytopenia was defined as low platelet counts on both POD 3 and POD 5. This was based on previous reports describing that low platelet counts on POD 5 were related to graft loss and severe postoperative morbidity [8, 13] .
Outcome parameters
Endoscopic retrograde cholangiopancreatogram (ERCP) was performed for clinical suspicion of stricture. Indications for ERCP included abdominal pain, fever, jaundice, and abnormal liver function tests. Clinically significant BAS was defined as a focal stenosis more than 50% at the anastomosis detected by ERCP, which was considered as incidence of BAS in the analysis. When the recipient bile duct was narrower than the donor bile duct, but there was no focal stenosis at the anastomosis, this was considered as a donor to recipient size mismatch, but not BAS. Early allograft dysfunction (EAD) was defined by bilirubin ≥10 mg/dl on day 7, international normalized ratio ≥1.6 on day 7, and AST or ALT >2000 IU/l within the first 7 days, according to a modified version of the original EAD definition in the Model for End-Stage Liver Disease (MELD) era of organ sharing [14] .
Statistical analysis
Discrete variables were compared using the chi-square test or Fisher's exact test. Continuous variables are expressed as the median, minimum, and maximum and were compared using t-test. In the ROC analysis, the Youden Index and its 95% confidence intervals (CI) were used for deciding the cutoff value of postoperative platelet count. The 95% CI was estimated using a nonparametric bootstrap approach (5000 times of resampling). Statistical analyses were performed using the SPSS 21.0 (SPSS Inc., Chicago, IL, USA) and SAS software version 9.4 (SAS Institute, Cary, NC, USA). Variables in the univariate analyses were included in a multivariate logistic regression analysis by our clinical expertise. P < 0.05 was considered statistically significant.
Results
Demographics and clinical outcomes
The median follow-up was 5.6 years. Peritransplant platelet counts in patients with and without BAS Peritransplant platelet dynamics are presented in Fig. 1 . Platelet counts in both groups reached minimum values on POD 3. Pre-and post-transplant platelet counts within 5 days after LT were significantly lower in patients with BAS than those without BAS. An optimal cutoff value of postoperative platelet count on POD 3 and 5 for progression of BAS was acquired by ROC analysis. Sensitivity, specificity, sensitivity + specificity À 1, Youden Index, 95% CI of Youden Index, and area under curve for several cut points on POD 3 and 5 are shown in Table 2 . Youden Indexes showed optimal cutoff values of 41 9 1000/ll on POD 3 and 53 9 1000/ll on POD 5. Persistent postoperative thrombocytopenia was defined as platelet counts <41 9 1000/ll and <53 9 1000/ll on POD 3 and POD 5, respectively. Persistent postoperative thrombocytopenia was found in 203 patients.
Prediction of BAS
The risk factors for the development of BAS were compared by a logistic regression model (Table 3) . Recipient male gender [odds ratio (OR) = 1.56, P = 0.03], disease type viral hepatitis C (OR = 1.46, P = 0.04), MELD score ≥30 (OR = 2.20, P < 0.001), HTK solution (OR = 1.71, P = 0.03), and persistent postoperative thrombocytopenia (OR = 2.49, P < 0.001) were significantly associated with the development of BAS on univariate analysis. A multivariate logistic regression analysis was performed with 14 variables [recipient age ≥60, recipient male gender, disease type of viral hepatitis C, MELD score ≥30, preoperative refractory ascites (grade ≥3), macrosteatosis ≥25%, liver donor risk index (LDRI) ≥1.7, HA flow/graft weight ratio, suture type of biliary reconstruction, HTK solution, biliary stent, EAD, bile leak, and persistent postoperative thrombocytopenia]. Persistent postoperative thrombocytopenia (OR = 2.38, P = 0.01) became the only independent risk factor for development of BAS.
Prediction of persistent postoperative thrombocytopenia
The contributing factors for persistent postoperative thrombocytopenia were compared using a logistic regression model (Table 4) . Body mass index (BMI) ≥30 (OR = 1.40, P = 0.04), MELD score ≥30 (OR = 2.64, P < 0.001), preoperative encephalopathy (OR = 1.92, P = 0.02), estimated blood loss (OR = 1.01, per 100 ml up, P = 0.04), HTK solution (OR = 1.70, P = 0.005), red blood cell transfusion (OR = 1.08, P < 0.001), fresh frozen plasma transfusion (OR = 1.04, P = 0.001), platelet transfusion (OR = 1.02, P < 0.001), EAD (OR = 1.54, P = 0.01), and postoperative platelet transfusion (OR = 4.57, P < 0.001) were associated with persistent postoperative thrombocytopenia. Estimated blood loss, red blood cell transfusion, fresh frozen plasma transfusion, and perioperative platelet transfusion were highly correlated as calculated by the Pearson correlation coefficient. Therefore, estimated blood loss was included in the final multivariate model. Because donor age and cold ischemia time are components of LDRI, LDRI ≥1.7 was included in the multivariate model instead of these two variables. A multivariate logistic regression analysis was performed with 20 variables (recipient age ≥60, recipient male gender, Caucasian, disease type viral Figure 1 Perioperative platelet dynamics in patients with or without biliary anastomotic stricture (BAS). Platelet counts in both groups reached minimum counts on the postoperative day 3. Preoperative and postoperative platelet counts within 5 days after liver transplantation were significantly lower in patients with BAS. Median values are shown. *P < 0.05. **P < 0.01. *Platelet count <41 9 1000/ll on POD 3 and platelet count <53 9 1000/ll on POD 5.
HTK solution, and EAD)
. This multivariable analysis demonstrated that estimated blood loss became the only independent contributing factor for persistent postoperative thrombocytopenia (OR = 1.01, per 100 ml up, P = 0.04).
Discussion
Despite recent advances in organ preservation, surgical technique and immunosuppression, the incidence of BAS continues to range from 5% to 15% after deceased donor LT [1] . The pathogenesis of BAS is known to be due to suboptimal techniques, local ischemia, increased donor age, graft steatosis, cytomegalovirus infection, male gender recipient, acute cellular rejection, high MELD score, etc. [2, [15] [16] [17] [18] . Several studies have reported bile leak to be an independent risk factor and the internal stent to be independent protective factors [19, 20] . Further, DCD grafts and living donor grafts bear markedly higher risk [12, 21] . In contrast, whether duct-to-duct anastomosis, or hepaticojejunostomy are risk factors for progression of BAS remains unknown, and no significant differences have been observed between interrupted versus continuous suture [19] . We identified persistent postoperative thrombocytopenia to be the only risk factor for progression of BAS. No direct Estimated blood loss, red blood cell transfusion, fresh frozen plasma transfusion, and perioperative platelet transfusion were highly correlated. Therefore, estimated blood loss was included in the final multivariate model. associations were observed in terms of recipient, donor, and surgical factors including suture type of biliary reconstruction and use of internal stent. It was notable that HTK solution tended to relate with progression of BAS. This result was compatible with a recent study from the European Liver Transplant Registry, reporting that HTK solution was independently associated with a 10% increased risk of graft loss with higher incidence of primary nonfunction, biliary complications, and infectious complications than other solutions [22] . Further, in our series, HA flow/graft weight ratio and HA flow/body weight ratio (data not shown) did not relate with BAS or persistent postoperative thrombocytopenia. It is known that the bile duct is mainly supplied by the hepatic artery, and a decrease in HA flow can cause biliary complications. Kim et al.
[23] described HA flow/body weight ratio of <5 ml/ min/kg to be associated with higher rates of biliary complications. Hashimoto et al.
[24] reported a relationship between impaired HA buffer response and early development of biliary complications. In our study, the timing of HA flow measurement was dependent on each surgeon's judgment and it was not unified. In some cases, flow was measured immediately after HA anastomosis, while in other cases it was delayed until later in the case. This might result in a difference from previous articles. Platelets are the smallest blood components that contain biophysiological substances, including hepatocyte growth factor (HGF), tumor necrosis factor-a, interleukin-6, serotonin, and insulin growth factor-1 [25] . Following activation, platelets release these substances to either enhance or limit tissue injury. The relationship between platelets and LT was reported from the late 1990s, and thrombocytopenia after LT was found to be associated with poor graft and overall survivals [4, 7] . However, this relationship has remained unelucidated. Recently, Lesurtel et al. [8] proposed the 60-5 criteria, in which a platelet count <60,000/ll on POD 5 was an independent risk factor associated with severe postoperative complications, early graft failure, and patient mortality. In recent years, experimental studies have demonstrated that platelets play an important role in attenuating fibrosis in the liver [26] . Murata et al. [10] reported that platelets accumulated in the fibrotic liver immediately after hepatectomy, promoted liver regeneration and decreased liver fibrosis. Takahashi et al. [27] found that platelets enhanced HGF release from Kupffer cells and suppressed activation of hepatic stellate cells, the cell primarily responsible for liver fibrosis progression. Ikeda et al. [28] stated that adenine nucleotides enriched in platelets suppressed hepatic stellate cell activation via the adenosine-cyclic adenosine monophosphate signaling pathway.
In this study, we focused on thrombocytopenia within 5 days after LT based on the results from previous reports showing that low platelet counts on POD 5 were a risk factor for graft loss and severe postoperative morbidity [8, 13] . We defined persistent postoperative thrombocytopenia as platelet count <41 9 1000/ll on POD 3 and platelet count <53 9 1000/ll on POD 5, according to the result from ROC analyses and Youden indexes. There are several considerations regarding our results. First, it remained controversial whether low platelet counts were merely sequelae of worse post-transplant graft function. In our study, there was no association between BAS and EAD, which is a wellaccepted surrogate marker of early graft function [14] . Second, peritransplant thrombocytopenia can be a consequence of splenic sequestration, reflecting severity of portal vein hypertension. Our results showed no association between persistent postoperative thrombocytopenia and preoperative clinical signs of portal hypertension, including existence of refractory ascites or preoperative encephalopathy. Considering previous experimental evidence [10, [26] [27] [28] , we hypothesize that more platelets accumulate in the bile duct in patients with high platelet counts. This may result in release of higher concentrations of growth factors, such as HGF and adenine nucleotides, which suppress fibroblast function and attenuate excessive fibrotic healing at the anastomosis.
Our results suggest that keeping post-transplant platelet counts higher by minimizing intraoperative blood loss could indirectly avoid progression of post-transplant BAS. These results are compatible with the study from Selvalkular et al. [29] who reported that increased intraoperative blood loss was a predictor for post-transplant biliary complications including BAS after LT. The current options to increase platelet counts include platelet transfusion, thrombopoietin mimetic agents, thrombopoietin-receptor agonists, splenectomy, and ligation of the splenic artery. Recent reports demonstrate that platelet transfusion promotes graft regeneration after living donor LT [30,31], whereas our results showed that platelet transfusion was found to be a risk factor for persistent postoperative thrombocytopenia, which correlated with progression of BAS. This might be because patients who required platelet transfusion were more likely to have a complicated surgery, leading to larger amount of blood loss and intraoperative coagulopathy, which might mask the positive effect of platelets. Further, in our study, splenic arterial ligation did not play a role in preventing BAS or persistent postoperative thrombocytopenia. We recently reported that postoperative thrombocytopenia might be associated with poor liver graft survival, and suggested that medical therapies to enhance peritransplant platelet count would be beneficial to improve liver graft outcomes [13] . Currently, we are planning to investigate a possible prognostic impact of thrombopoietin-receptor agonists on liver graft survival. Similarly, maintaining peritransplant platelet count by thrombopoietin-receptor agonists or other medical and surgical therapies may decrease a risk of BAS after LT. Further investigations would be warranted to determine possible effects of these platelet therapies on incidence of BAS.
This study has some limitations. First, the data was retrospective in nature. In addition, despite the relatively large number of cases, the study is from a single center, and the results were influenced by the internal practice pattern by each transplant anesthesia and surgical team, which may limit generalizability. Second, our study did not demonstrate the direct evidence that platelets suppress BAS after LT. Despite these limitations, platelets appear to play an important role in LT and additional studies may translate into viable methods for reducing risk and improving outcomes in this patient population.
In conclusion, we demonstrated for the first time that low platelet count is associated with progression of BAS after LT. Keeping platelet count high by minimizing intraoperative blood loss could potentially reduce incidence of post-transplant BAS. 
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